Table 5.

Adjusteda ORs and 95% CIs for associations of regular aspirin use with prostate cancer in men with high stageb disease compared with population controls

TotalAAEA
ControlCasecOR (95% CI)ControlCaseOR (95% CI)ControlCaseOR (95% CI)
Did you take aspirin regularly 1 year prior to interview?
No441 (46)63 (61)Ref.233 (52)39 (80)Ref.208 (40)24 (44)Ref.
Yes529 (54)41 (39)0.62 (0.39–0.97)220 (48)10 (20)0.26 (0.11–0.60)309 (60)31 (56)1.10 (0.60–2.03)
In the past 5 years, did you take at least 1 tablet daily?
No467 (46)65 (58)Ref.242 (50)39 (74)Ref.225 (42)26 (43)Ref.
Yes556 (54)48 (42)0.75 (0.49–1.15)239 (50)14 (26)0.35 (0.17–0.73)317 (58)34 (57)1.25 (0.69–2.25)
In the past 5 years, how long did you regularly take aspirin?
Did not use441 (43)63 (57)Ref.233 (49)39 (75)Ref.208 (39)24 (41)Ref.
≤3 years174 (17)20 (18)0.86 (0.49–1.51)89 (19)7 (13)0.48 (0.19–1.23)85 (16)13 (22)1.54 (0.72–3.29)
>3 years401 (39)28 (25)0.59 (0.35–0.97)157 (33)6 (12)0.22 (0.08–0.60)244 (45)22 (37)1.06 (0.55–2.05
Ptrend = 0.04PTrend<0.01Ptrend = 0.99
Among users who took at least 1 tablet daily, how long did they regularly take aspirin?
Did not use467 (46)65 (59)Ref.242 (51)39 (75)Ref.225 (42)26 (42)Ref.
≤3 years158 (16)20 (18)1.04 (0.59–1.82)82 (17)7 (13)0.54 (0.21–1.38)76 (14)13 (23)1.83 (0.86–3.91)
>3 years390 (38)26 (23)0.58 (0.35–0.98)154 (33)6 (12)0.24 (0.09–0.62)236 (44)20 (35)1.01 (0.52–1.96)
Ptrend = 0.05PTrend<0.01Ptrend = 0.95
• NOTE: Column total sums that differ are due to missing data, N (%). Bolded data indicate significant associations in the logistic regression analysis.

• aUnconditional logistic regression adjusted for age at study entry, BMI (kg/m2), diabetes (yes/no), education (high school or less, some college, college, professional school), family history of prostate cancer (first-degree relatives, yes/no), race (not included in stratified analysis), smoking history (never, former, current), Tylenol (yes/no), and pain relievers not containing Tylenol or aspirin-containing compounds (yes/no).

• bHigh stage includes men with pathologically confirmed T3 or T4 disease.

• cCases recruited within 1 year after disease diagnosis with an average interval between diagnosis and enrollment of 4.8 months.